Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 February 2004, Vol. 103, No. 3, pp. 804-810.
Prepublished online as a Blood First Edition Paper on September 25, 2003; DOI 10.1182/blood-2003-05-1426.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-05-1426v1
103/3/804    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, B. D.
Right arrow Articles by Lillicrap, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, B. D.
Right arrow Articles by Lillicrap, D.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Gene Therapy
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

GENE THERAPY

Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A

Brian D. Brown, Chang Xin Shi, Sandra Powell, David Hurlbut, Frank L. Graham, and David Lillicrap

From the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada; and Departments of Biology and Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Two helper-dependent (HD) adenoviral vectors encoding a canine factor VIII B-domain–deleted transgene (cFVIII) were constructed and evaluated in 4 hemophilia A dogs. One vector was regulated by the cytomegalovirus (CMV) promoter (HD-CMV-cFVIII), while the other vector contained a tissue-restricted promoter comprised of the human FVIII proximal promoter with an upstream concatemer of 5 hepatocyte nuclear factor 1 binding sites (HD-HNF-cFVIII). We detected no toxicity at low dose (5 x 1011 vp/kg), but at higher vector doses (> 1 x 1012 vp/kg) transient hepatotoxicity and thrombocytopenia were observed. Low-level increases in FVIII activity were detected in all 3 HD-HNF-cFVIII–treated dogs, which corresponded with decreased whole blood clotting times. None of the animals receiving the HD-HNF-cFVIII vector developed FVIII inhibitors, and in 1 of the 3 animals, FVIII activity was sustained for over 6 months after treatment. One animal, which received the HD-CMV-cFVIII vector, achieved peak levels of FVIII above 19 000 mU/mL, but FVIII activity disappeared within 1 week, coincident with the development of a potent anti–canine FVIII antibody response. This study supports previous demonstrations of improved safety using HD gene transfer and suggests that these vectors can provide transient FVIII expression with minimal, acute toxicity in the absence of inhibitor formation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Gutted adenoviral vectors in hemophilia A
Katherine A. High
Blood 2004 103: 751-752. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
D. E. Sabatino, C. F. Freguia, R. Toso, A. Santos, E. P. Merricks, H. H. Kazazian Jr, T. C. Nichols, R. M. Camire, and V. R. Arruda
Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
Blood, November 12, 2009; 114(20): 4562 - 4565.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. D. James, S. Raut, G. E. Rivard, M.-C. Poon, M. Warner, S. McKenna, J. Leggo, and D. Lillicrap
Aminoglycoside suppression of nonsense mutations in severe hemophilia
Blood, November 1, 2005; 106(9): 3043 - 3048.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Xu, T. C. Nichols, R. Sarkar, S. McCorquodale, D. A. Bellinger, and K. P. Ponder
Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy
PNAS, April 26, 2005; 102(17): 6080 - 6085.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. A. F. V. Goncalves, G. P. van Nierop, M. R. Tijssen, P. Lefesvre, S. Knaan-Shanzer, I. van der Velde, D. W. van Bekkum, D. Valerio, and A. A. F. de Vries
Transfer of the Full-Length Dystrophin-Coding Sequence into Muscle Cells by a Dual High-Capacity Hybrid Viral Vector with Site-Specific Integration Ability
J. Virol., March 1, 2005; 79(5): 3146 - 3162.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020